In line with these findings and with the observation that sphingolipid metabolic reprogramming plays an important role in melanoma progression [43], analysis of human specimens ranging from common nevi to stage IV melanoma demonstrated a gradual increase in GALC expression during tumor progression that goes along with a decrease in ceramide levels [1]. The gene discussed is GALC; the disease is melanoma.